142 related articles for article (PubMed ID: 27230848)
1. [Molecular and Cellular Pathogenesis of Cherubism].
Ueki Y
Clin Calcium; 2016 Jun; 26(6):918-26. PubMed ID: 27230848
[TBL] [Abstract][Full Text] [Related]
2. SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.
Mukai T; Ishida S; Ishikawa R; Yoshitaka T; Kittaka M; Gallant R; Lin YL; Rottapel R; Brotto M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014 Dec; 29(12):2618-35. PubMed ID: 24916406
[TBL] [Abstract][Full Text] [Related]
3. Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.
Kittaka M; Mayahara K; Mukai T; Yoshimoto T; Yoshitaka T; Gorski JP; Ueki Y
J Bone Miner Res; 2018 Jan; 33(1):167-181. PubMed ID: 28914985
[TBL] [Abstract][Full Text] [Related]
4. The role of SH3BP2 in the pathophysiology of cherubism.
Reichenberger EJ; Levine MA; Olsen BR; Papadaki ME; Lietman SA
Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S5. PubMed ID: 22640988
[TBL] [Abstract][Full Text] [Related]
5. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.
Yoshitaka T; Ishida S; Mukai T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014; 29(5):1170-82. PubMed ID: 24978678
[TBL] [Abstract][Full Text] [Related]
6. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
7. Jawing about TNF: new hope for cherubism.
Novack DV; Faccio R
Cell; 2007 Jan; 128(1):15-7. PubMed ID: 17218248
[TBL] [Abstract][Full Text] [Related]
8. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism.
Levaot N; Voytyuk O; Dimitriou I; Sircoulomb F; Chandrakumar A; Deckert M; Krzyzanowski PM; Scotter A; Gu S; Janmohamed S; Cong F; Simoncic PD; Ueki Y; La Rose J; Rottapel R
Cell; 2011 Dec; 147(6):1324-39. PubMed ID: 22153076
[TBL] [Abstract][Full Text] [Related]
9. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
Ueki Y; Lin CY; Senoo M; Ebihara T; Agata N; Onji M; Saheki Y; Kawai T; Mukherjee PM; Reichenberger E; Olsen BR
Cell; 2007 Jan; 128(1):71-83. PubMed ID: 17218256
[TBL] [Abstract][Full Text] [Related]
10. Cherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages.
Prod'Homme V; Boyer L; Dubois N; Mallavialle A; Munro P; Mouska X; Coste I; Rottapel R; Tartare-Deckert S; Deckert M
J Clin Invest; 2015 Apr; 125(4):1396-400. PubMed ID: 25705883
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow transplantation improves autoinflammation and inflammatory bone loss in SH3BP2 knock-in cherubism mice.
Yoshitaka T; Kittaka M; Ishida S; Mizuno N; Mukai T; Ueki Y
Bone; 2015 Feb; 71():201-9. PubMed ID: 25445458
[TBL] [Abstract][Full Text] [Related]
12. [SH3BP2 heterozygous mutation amplifies macrophage inflammatory responses to infection in a mouse model of cherubism].
Deckert M; Prod'Homme V
Med Sci (Paris); 2015; 31(6-7):589-91. PubMed ID: 26152156
[No Abstract] [Full Text] [Related]
13. Cherubism gene Sh3bp2 is important for optimal bone formation, osteoblast differentiation, and function.
Mukherjee PM; Wang CJ; Chen IP; Jafarov T; Olsen BR; Ueki Y; Reichenberger EJ
Am J Orthod Dentofacial Orthop; 2010 Aug; 138(2):140.e1-140.e11; discussion 140-1. PubMed ID: 20691350
[TBL] [Abstract][Full Text] [Related]
14. SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism.
Lietman SA; Prescott NL; Hicks DG; Westra WH; Levine MA
Clin Orthop Relat Res; 2007 Jun; 459():22-7. PubMed ID: 17545756
[TBL] [Abstract][Full Text] [Related]
15. Molecular and cellular characterizations of human cherubism: disease aggressiveness depends on osteoclast differentiation.
Kadlub N; Sessiecq Q; Mandavit M; L'Hermine AC; Badoual C; Galmiche L; Berdal A; Descroix V; Picard A; Coudert AE
Orphanet J Rare Dis; 2018 Sep; 13(1):166. PubMed ID: 30236129
[TBL] [Abstract][Full Text] [Related]
16. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties.
Wang CJ; Chen IP; Koczon-Jaremko B; Boskey AL; Ueki Y; Kuhn L; Reichenberger EJ
Bone; 2010 May; 46(5):1306-15. PubMed ID: 20117257
[TBL] [Abstract][Full Text] [Related]
17. Adaptor protein 3BP2 and cherubism.
Hatani T; Sada K
Curr Med Chem; 2008; 15(6):549-54. PubMed ID: 18336269
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation.
Lietman SA; Kalinchinko N; Deng X; Kohanski R; Levine MA
Hum Mutat; 2006 Jul; 27(7):717-8. PubMed ID: 16786512
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor necrosis factor treatment in cherubism--clinical, radiological and histological findings in two children.
Hero M; Suomalainen A; Hagström J; Stoor P; Kontio R; Alapulli H; Arte S; Toiviainen-Salo S; Lahdenne P; Mäkitie O
Bone; 2013 Jan; 52(1):347-53. PubMed ID: 23069372
[TBL] [Abstract][Full Text] [Related]
20. Bone dynamics and inflammation: lessons from rare diseases.
Matsumoto Y; Rottapel R
Immunol Med; 2020 Jun; 43(2):61-64. PubMed ID: 31999934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
